RecruitingNCT06113237

Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant

Sponsor

Jazz Pharmaceuticals

Enrollment

50 participants

Start Date

Aug 5, 2025

Study Type

OBSERVATIONAL

Conditions

Pregnancy Maternal Complications Pregnancy Complication Birth Outcomes, Adverse

Summary

The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Epidiolex for people with birth outcomes, adverse, maternal complications, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include women.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEpidiolex

Oral solution

Locations(2)

United Biosource LLC

Morgantown, West Virginia, United States

Vivantes Humboldt-Klinikum Klinik für Neurologie

Berlin, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06113237

Related Trials

Determinant Factors in Excessive Gestational Weight Gain: Physical Activity, Nutritional Status, and Anxiety

NCT073684651 location

PregnAncy-Related Aortic DISsEction in China

NCT076722104 locations